Argentinean Initiative of Stroke in the Young and Fabry Disease (FD): Final Results (P3.229)

CONCLUSIONS: FD was identified in only 0.3[percnt] of patients in this first Latin American study. A large number of non pathogenic mutations were present and it is essential that they should not be confused with pathogenic mutations to avoid unnecessary enzyme replacement treatmentDisclosure: Dr. Reisin has received personal compensation for activities with Shire HGT. Dr. Mazziotti has nothing to disclose. Dr. Leon Cejas has nothing to disclose. Dr. Zinnerman has nothing to disclose. Dr. Bonardo has nothing to disclose. Dr. Fernandez Pardal has nothing to disclose. Dr. Martinez has nothing to disclose. Dr. Sposato has nothing to disclose. Dr. Ameriso has nothing to disclose. Dr. Bendersky has nothing to disclose. Dr. Nofal has nothing to disclose. Dr. Cairola has nothing to disclose. Dr. Jure has nothing to disclose. Dr. Sotelo has nothing to disclose. Dr. Rozenfeld has nothing to disclose. Dr. Ceci has nothing to disclose. Dr. Casas-Parera has nothing to disclose. Dr. Sanchez Luceros has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Reisin, R., Mazziotti, J., Leon Cejas, L., Zinnerman, A., Bonardo, P., Fernandez Pardal, M., Martinez, A., Sposato, L. A., Ameriso, S., Bendersky, E., Nofal, P., Cairola, P., Jure, L., Sotelo, A., Rozenfeld, P., Ceci, R., Casas-Parera, I., Sanchez Luceros Tags: Stroke in the Young Source Type: research